spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Synpromics announces a research collaboration with GE Healthcare to extend the toolbox for production of biologics

Synpromics

It will see the development of a complex bar-coded library of synthetic promoters

Edinburgh, UK, 4th January 2017 – Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announce a research collaboration with GE Healthcare to jointly develop customised synthetic promoters optimised for GE Healthcare’s proprietary biopharmaceutical manufacturing platform.

Synpromics will develop a complex bar-coded library of synthetic promoters, using its proprietary PromPT™ platform, for extensive screening in GE Healthcare’s Chinese Hamster Ovary (CHO)-based expression system. The resulting characterised promoter toolbox is anticipated to have broad applicability for increasing the yield of a range of biopharmaceuticals, including proteins difficult to manufacture. GE Healthcare is paying an upfront technology access fee and will have the rights to commercialise the improved platform.

Dr David Venables, CEO of Synpromics, commented, “We are delighted to be working with GE Healthcare, a world leading technology innovator to develop and commercialise our novel synthetic promoter platform. We believe our synthetic promoters will provide a much more efficient production system and we’re aiming to help GE Healthcare boost efficiency for its biopharma customers.”

“We are happy to be able to collaborate with Synpromics on developing enhanced tools for manufacturing biologics and thereby support our customers in their production efforts,” said Morgan Norris, GM, Upstream and Cell Culture for GE Healthcare’s Life Sciences business.

About Synpromics
Synpromics is a private company focused on commercialising its proprietary technology in the emerging field of synthetic biology by developing customised synthetic promoters. The company has partnership deals with a number of gene therapy companies including AGTC, Adverum and uniQure.

Synpromics technology gives biological researchers, developers and manufacturers unprecedented control of gene expression through the ability to create a comprehensive portfolio of man-made DNA sequences. This is a highly disruptive technology as most of the currently used promoters are natural viral or gene specific promoters. Synpromics’ products comprise patented synthetic promoters that are designed to regulate genes in a highly specific manner. For more information see www.synpromics.com

About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE Healthcare (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions GE Healthcare helps medical professionals deliver great healthcare to their patients. www.gehealthcare.com

Media Contact
Deborah Cockerill
Sciad Communications Ltd
+44 (0)7930 317729
deborah@sciad.com

Corporate Contact
Dr David Venables, CEO
Synpromics Ltd
+44 (0)7825 323439
david.venables@synpromics.com
phone +44 (0) 131 651 9662
email info@synpromics.com
web www.synpromics.com
email Roslin Innovation Centre, Easter Bush Campus, Midlothian, EH25 9RG
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Charles River Laboratories Makes Investments in High-Throughput Screening Infrastructure

WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 1, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a new agreement which grants Charles River commercial access to AstraZeneca’s (NYSE: AZN) high-throughput screening (HTS) and compound management infrastructure. Through the agreement, Charles River will perform HTS programs for its clients utilizing AstraZeneca’s state-of-the-art HTS facility.
More info >>


White Papers

Running Smarter Trials With Data-Driven Monitoring

PAREXEL

Clinical monitoring remains one of the most important and most costly activities in the clinical research paradigm.  Monitoring provides the operational transparency required by investigators, sponsors, and regulators to make informed decisions about site performance, patient safety, and overall study progress. Yet unlike many clinical trial activities, which have been steadily transformed by technology, the monitoring function itself has changed little.
More info >>

Industry Events

ASPIRE: International EDGE Conference

28 February - 1 March 2018, The Vox Conference Centre, Birmingham

The ASPIRE international conference is taking place on the 28th February and 1st March 2018 at the Vox Conference Centre in Birmingham. The conference brings together members of the research community including research professionals from the NHS, Clinical Trial Networks and international organisations. The ASPIRE conference will allow delegates to share knowledge and best practise with the focus on enhancing the efficiency and productivity of clinical research across the UK and beyond.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement